Pacira BioSciences, Inc. (PCRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of PCRX. The 7-day demo opens the 1M and 3M ranges and puts PCRX on your watchlist.
Start 7-day demoLatest PCRX insider trades
- Lauren Riker - OfficerOpen-market sale$218K
Jonathan Slonin - OfficerOpen-market sale$71K
About Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
- BRISBANE, CA
- 829
- 2011
- XNAS
PCRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 9,040 | $289K |
| Option exercise | 2 | 12,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PCRX insider transactions (Form 4)
5240 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lauren Riker - Officer | Option exercise | Common Stock | 6,000 footnote F1 | $32.35 | $194K | |
| Lauren Riker - Officer | Open-market sale | Common Stock | 6,000 footnote F1 | $36.32 | $218K | |
| Lauren Riker - Officer | Option exercise | Stock Option (Right to Buy) | 6,000 footnote F1 | $0.00 | - | |
| ||||||
| Jonathan Slonin - Officer | Open-market sale | Common Stock | 3,040 | $23.23 | $71K | |
| Samit Hirawat - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Samit Hirawat - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| ||||||
| Lauren Riker - Officer | Open-market sale | Common Stock | 6,115 footnote F1 | $23.50 | $144K | |
| ||||||
| Christopher Christie - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| Christopher Christie - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| ||||||
 Thomas G. Wiggans - Director | Grant or award | Stock Option (Right to Buy) | 32,675 | $0.00 | - | |
 Alethia Young - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| Alethia Young - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| ||||||
| Michael J. Yang - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| Michael J. Yang - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| ||||||
| Marcelo Bigal - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| Marcelo Bigal - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| ||||||
 Mark Froimson - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| Mark Froimson - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| ||||||
| Laura Brege - Director | Grant or award | Common Stock | 6,405 footnote F1 | $0.00 | - | |
| Laura Brege - Director | Grant or award | Stock Option (Right to Buy) | 10,891 | $0.00 | - | |
| ||||||
| Lauren Riker - Officer | Tax withholding / forfeiture | Common Stock | 3,187 footnote F1 | $22.32 | $71K | |
| ||||||
| Jonathan Slonin - Officer | Tax withholding / forfeiture | Common Stock | 4,728 footnote F1 | $22.32 | $106K | |
| ||||||
| Kristen Williams - Officer | Tax withholding / forfeiture | Common Stock | 8,528 footnote F1 | $22.32 | $190K | |
| Kristen Williams - Officer | Open-market sale | Common Stock | 10,259 footnote F2 | $22.27 | $228K | |
| ||||||
| Shawn Cross - Officer | Option exercise | Common Stock | 12,941 footnote F1 | $16.45 | $213K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 12,941 footnote F1 | $25.16 footnote F2 | $326K | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 12,941 footnote F1 | $0.00 | - | |
| ||||||
| Shawn Cross - Officer | Option exercise | Common Stock | 7,714 footnote F1 | $16.45 | $127K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 7,714 footnote F1 | $25.14 footnote F2 | $194K | |
| Shawn Cross - Officer | Option exercise | Common Stock | 2,845 footnote F1 | $16.45 | $47K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 2,845 footnote F1 | $25.01 footnote F3 | $71K | |
| Shawn Cross - Officer | Option exercise | Common Stock | 1,500 footnote F1 | $16.45 | $25K | |
| Shawn Cross - Officer | Open-market sale | Common Stock | 1,500 footnote F1 | $25.01 footnote F3 | $38K | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 7,714 footnote F1 | $0.00 | - | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 2,845 footnote F1 | $0.00 | - | |
| Shawn Cross - Officer | Option exercise | Stock Option (Right to Buy) | 1,500 footnote F1 | $0.00 | - | |
| ||||||
 Mark A. Kronenfeld - Director | Grant or award | Common Stock | 6,163 | $0.00 | - | |
| Jonathan Slonin - Officer | Open-market sale | Common Stock | 3,261 footnote F1 | $22.82 | $74K | |
| ||||||
| Mark Froimson - Director | Open-market sale | Common Stock | 500 | $21.81 | $11K | |
| Shawn Cross - Officer | Grant or award | Common Stock | 49,091 footnote F1 | $0.00 | - | |
| ||||||
| Kristen Williams - Officer | Grant or award | Common Stock | 54,546 footnote F1 | $0.00 | - | |
| ||||||
| Brendan Teehan - Officer | Grant or award | Common Stock | 51,714 footnote F1 | $0.00 | - | |
| ||||||
| Lauren Riker - Officer | Grant or award | Common Stock | 19,273 footnote F1 | $0.00 | - | |
| ||||||
| Jonathan Slonin - Officer | Grant or award | Common Stock | 54,546 footnote F1 | $0.00 | - | |
| ||||||
| Frank D. Lee - Officer | Grant or award | Common Stock | 261,818 footnote F1 | $0.00 | - | |
| ||||||
| Lauren Riker - Officer | Tax withholding / forfeiture | Common Stock | 2,751 footnote F1 | $20.54 | $57K | |
| Lauren Riker - Officer | Open-market sale | Common Stock | 4,000 footnote F2 | $20.81 footnote F3 | $83K | |
| ||||||
| Kristen Williams - Officer | Tax withholding / forfeiture | Common Stock | 17,134 footnote F1 | $20.54 | $352K | |
| Kristen Williams - Officer | Open-market sale | Common Stock | 13,137 footnote F2 | $20.53 | $270K | |
| ||||||
| Jonathan Slonin - Officer | Tax withholding / forfeiture | Common Stock | 6,168 footnote F1 | $20.54 | $127K | |
| ||||||
| Brendan Teehan - Officer | Tax withholding / forfeiture | Common Stock | 5,182 footnote F1 | $20.54 | $106K | |
| ||||||
| Frank D. Lee - Officer | Tax withholding / forfeiture | Common Stock | 41,488 footnote F1 | $20.54 | $852K | |
| ||||||
Item 1.01, 7.01, 9.01
Item 2.02, 9.01
Item 1.01, 7.01, 9.01
Item 5.02, 5.07, 8.01, 9.01
Recent PCRX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| RIKER LAUREN | Officer | 6,000 | $218K | View on EDGAR | |
| SLONIN JONATHAN | Officer | 3,040 |
PCRX insider trading FAQ
What is the latest insider trade for PCRX?
Pacira BioSciences, Inc. (PCRX) had 2 insider filings in the last 90 days, with the most recent on 2026-10-09. The full record for PCRX runs to 40 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PCRX stock?
No insider purchases of PCRX were filed in the last 90 days.
How many insiders are selling PCRX stock?
2 insider sales of PCRX were filed in the last 90 days, totaling $289K.
Where can I see PCRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PCRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lauren Riker view on EDGAR
- - Jonathan Slonin view on EDGAR
- - Samit Hirawat view on EDGAR
- - Lauren Riker view on EDGAR
- - Christopher Christie view on EDGAR
- - Thomas G. Wiggans view on EDGAR
- - Alethia Young view on EDGAR
- - Michael J. Yang view on EDGAR
- - Marcelo Bigal view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PCRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PCRX with a 7-day demo
- PCRX on your watchlist
- Every PCRX Form 4 filing on record
- Up to 3 months of PCRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
